Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Fulcrum Therapeutics, Inc. | President & Chief Executive Officer, Director | Common Stock | 193K | $1.5M | $7.76 | Jul 3, 2024 | Direct |
Fulcrum Therapeutics, Inc. | President & Chief Executive Officer, Director | Stock option - Right to Buy | 2.28M | Jul 3, 2024 | Direct | ||
PhaseBio Pharmaceuticals Inc | Director | Common Stock | 3.75K | May 19, 2023 | Direct | ||
PhaseBio Pharmaceuticals Inc | Director | Restricted Stock Units | 0 | May 19, 2023 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
FULC | Fulcrum Therapeutics, Inc. | Jul 3, 2024 | 2 | $491K | 4 | Jul 8, 2024 | President & Chief Executive Officer, Director |
FULC | Fulcrum Therapeutics, Inc. | Mar 4, 2024 | 1 | $492K | 4 | Mar 5, 2024 | President & Chief Executive Officer, Director |
FULC | Fulcrum Therapeutics, Inc. | Jul 1, 2023 | 0 | $0 | 3 | Jul 3, 2023 | President & Chief Executive Officer Exhibit Index: 24.1 Power of Attorney, Director |
PHASQ | PhaseBio Pharmaceuticals Inc | May 19, 2023 | 2 | $0 | 4 | May 19, 2023 | Director |
PHASQ | PhaseBio Pharmaceuticals Inc | May 19, 2022 | 2 | $0 | 4 | May 20, 2022 | Director |
PHASQ | PhaseBio Pharmaceuticals Inc | Jun 3, 2021 | 1 | $0 | 4 | Jun 4, 2021 | Director |